Xilio Therapeutics Swings to Q4 Profit, Extends Cash Runway Through 2027
XLO sits 26% above its 52-week low of $6.465 on elevated volume (3.1× avg).
Summary
Xilio Therapeutics reported a Q4 net income of $10.36 million, a significant positive swing driven by higher collaboration and license revenue, primarily from agreements with AbbVie and Gilead. Crucially, the company announced it has extended its cash runway through the end of 2027. This positive financial update follows recent significant events for the company, including a $40 million capital raise and a 1-for-14 reverse stock split in early March, which often indicate financial pressures. The unexpected profit and extended cash runway provide a strong positive signal for this small-cap biotech, enhancing its financial stability and operational outlook. Additionally, Xilio provided pipeline updates, expecting to submit an IND for XTX501 in mid-2026 and start Phase 1 in H2 2026, alongside nominating a new T cell engager candidate in Q2 2026. Traders will be watching for continued progress on these pipeline milestones and further details on collaboration revenue streams.
At the time of this announcement, XLO was trading at $8.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.2M. The 52-week trading range was $6.47 to $16.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.